Sector News

Endo said to be jousting with Valeant, Shire to win Salix

February 18, 2015
Life sciences
With Valeant and Shire already said to be prepping bids for North Carolina’s Salix, it seems there’s a third wannabe suitor, too. Word on the street is that Endo International has come calling multiple times–and though Salix has shot Endo down, it’s still not going away.
 
The pain management-focused company and its advisers have sent several letters to Salix, a source told Reuters. And despite rejection, Endo is still interested in tangoing with the North Carolina drugmaker.
 
GI specialist Salix has drawn its fair share of takeover interest in recent years. Since an inventory snafu prompted investors to push for a sale, that interest has heated up. Rumor has it that serial acquirer Valeant Pharmaceuticals–looking to hop back into dealmaking after spending most of last year on a failed pursuit of Allergan ($AGN)–has lined up the financing necessary to make an offer. And Shire, which has a plenty of cash to throw around even after last month’s $5.2 billion pact for NPS Pharmaceuticals ($NPSP), isn’t far behind.
 
But while those companies may be deal-minded, the complexity of an acquisition may scare them off, the news service notes. Salix’s inventory problems are broad enough that the company is reissuing financial statements covering the last 7 quarters. The issues also triggered a management shakeup and scuttled at least one potential buyout; Allergan was looking to buy Salix as a way to dodge Valeant last year, but backed off because of the inventory snafu, The Wall Street Journal reported at the time. Other fines and litigation could still be on the way.
 
Endo is no stranger to M&A itself. CEO Rajiv De Silva, a former Valeant exec, seems to have taken a page from Valeant chief J. Michael Pearson’s playbook, with a string of several deals to his credit last year. Those included the buyout of Ireland’s Paladin Labs that helped it complete a tax inversion.
 
If Endo can win over Salix, the acquisition could reshape the company, Reuters notes. The drugmaker–still struggling after losing patent protection for top-seller Lidoderm in 2013–currently boasts a market cap of $14.3 billion, and Salix’s market cap stands at $9.5 billion.
 
By Carly Helfand
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]